Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
Authors:
Open Access
- 10 June 2021
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 16 (4) , 415-424
Abstract
Background For research with human participants to be ethical, risk must be in a favorable balance with potential benefits. Little is known about the risk/benefit ratio for pediatric cancer phase II trials testing targeted therapies. Objective Our aim was to conduct a systematic review of preliminary efficacy and safety profiles of phase II targeted therapy clinical trials in pediatric oncology. Methods Our protocol was prospectively registered in PROSPERO (CRD42020146491). We searched EMBASE and PubMed for phase II pediatric cancer trials testing targeted agents. We included solid and hematological malignancy studies published between 1 January, 2015 and 27 February, 2020. We measured risk using drug-related grade 3 or higher adverse events, and benefit by response rates. When possible, data were meta-analyzed. All statistical tests were two-sided. Results We identified 34 clinical trials (1202 patients) that met our eligibility criteria. The pooled overall response rate was 24.4% (95% confidence interval [CI] 14.5–34.2) and was lower in solid tumors, 6.4% (95% CI 3.2–9.6), compared with hematological malignancies, 55.1% (95% CI 35.9–74.3); p < 0.001. The overall fatal drug-related (grade 5) adverse event rate was 1.6% (95% CI 0.6–2.5), and the average drug-related grade 3/4 adverse event rate per person was 0.66 (95% CI 0.55–0.78). Conclusions We provide an estimate for the risks and benefits of participation in pediatric phase II cancer trials. These data may be used as an empirical basis for informed communication about benefits and burdens in pediatric oncology research.Keywords
Funding Information
- Narodowe Centrum Nauki (2015/18/E/HS1/00354)
This publication has 40 references indexed in Scilit:
- Nanoparticle Systems Reduce Systemic Toxicity in Cancer TreatmentNanomedicine, 2015
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical TrialsJournal of Clinical Oncology, 2015
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of SunitinibJNCI: Journal of the National Cancer Institute, 2015
- Quality of reporting of phase II trials: a focus on highly ranked oncology journalsAnnals of Oncology, 2014
- Gene-Targeting of Phd2 Improves Tumor Response to Chemotherapy and Prevents Side-ToxicityCancer Cell, 2012
- Alternate Endpoints for Screening Phase II StudiesClinical Cancer Research, 2009
- Three Steps to Protecting Pediatric Research Participants from Excessive RisksPLoS Clinical Trials, 2006
- A literature review on off-label drug use in childrenEuropean Journal of Pediatrics, 2005
- Clinical trials in childrenThe Lancet, 2004
- Pediatric Phase II Cancer Chemotherapy TrialsJournal of Pediatric Hematology/Oncology, 1997